Related Experiment Video
Updated: Sep 23, 2026
A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
Published on: May 14, 2013
Total plasma homocysteine and restenosis after percutaneous coronary angioplasty: current evidence
Guido Schnyder1, Gilles Rouvinez
1Division of Cardiology, UCSD Medical Center, University of California, San Diego, California 92103-8784, USA. g.schnyder@lycos.com
Insights
Lowering homocysteine levels may reduce restenosis after percutaneous coronary angioplasty (PTCA). This inexpensive therapy shows promise for improving outcomes and reducing adverse events in patients undergoing PTCA.
Area of Science:
- Cardiology
- Interventional Cardiology
- Vascular Biology
Background:
- Restenosis following percutaneous coronary angioplasty (PTCA) is a significant clinical challenge.
- Elevated homocysteine levels are implicated as a potential risk factor for restenosis.
Purpose of the Study:
- To evaluate the association between homocysteine levels and restenosis post-PTCA.
- To assess the efficacy of homocysteine-lowering therapy in mitigating restenosis and improving clinical outcomes.
Main Methods:
- A comprehensive literature review of MEDLINE-indexed studies was conducted.
- Meta-analysis of available data was performed to quantify risk reduction.
- Analysis included subgroup evaluation based on treatment modality (balloon angioplasty vs. stenting).
Main Results:
- Pooled data indicated a 22%-36% risk reduction in restenosis with lower homocysteine levels.
- A significant reduction (42%) was observed in balloon-only treated lesions.
- Homocysteine-lowering therapy demonstrated a 54% reduction in restenosis rates and a 40% decrease in major adverse events.
Conclusions:
- Plasma homocysteine is identified as a modifiable risk factor for restenosis after PTCA.
- Homocysteine-lowering therapy offers a safe, inexpensive, and effective adjunctive treatment strategy.
- Further research is warranted, but current evidence supports considering this therapy for patients undergoing PTCA.
Background:
Restenosis after percutaneous coronary angioplasty (PTCA) remains an important limitation of this procedure.
Aim:
To assess the relationship between homocysteine levels and restenosis after PTCA, and discuss the potential benefit of homocysteine-lowering therapy.
Method:
MEDLINE-based literature review.
Results:
The conflicting literature on the association between homocysteine levels and restenosis after PTCA can partially be explained by differences in methodology. Depending on the type of studies considered, a pooling of data resulted in a 22%-36% risk reduction of restenosis in lesions exposed to low homocysteine levels. The strongest reduction was found in balloon-only treated lesions (42%), while only a trend (14%) was seen in stented lesions. Based on the only available trial, homocysteine-lowering therapy yielded a 54% restenosis rate reduction, 76% in balloon-only treated lesions and 31% in stented lesions. Furthermore, homocysteine-lowering therapy provided a significant clinical benefit with a 40% relative reduction in major adverse events at 6 months' follow-up.
Conclusions:
This review suggests that plasma homocysteine is a modifiable risk factor for restenosis, which when lowered improves outcome after PTCA. This inexpensive treatment with virtually no side-effects could therefore be considered as adjunctive therapy for patients undergoing PTCA, while awaiting results from further studies.
Related Concept Videos
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:27Peripheral Artery Disease III: Interprofessional Care